ConcertAI
Founded Year
2017Stage
Series C | AliveTotal Raised
$320MValuation
$0000Last Raised
$150M | 3 yrs agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
-63 points in the past 30 days
About ConcertAI
ConcertAI specializes in clinical artificial intelligence and real-world data products within the healthcare sector. The company offers a suite of AI-driven solutions and services designed to optimize clinical trials, provide predictive patient insights, and support commercial healthcare solutions. ConcertAI primarily serves the oncology research and clinical development sectors. It was founded in 2017 and is based in Cambridge, Massachusetts.
Loading...
ESPs containing ConcertAI
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The real-world data providers market offers a variety of value propositions to the pharmaceutical industry, drug labs, and healthcare organizations. It provides access to diverse patient populations, longitudinal real-world data, and patient-powered or EHR-powered controls that can replicate real-world scenarios. This can help shorten drug development timelines, reduce patient recruitment burdens …
ConcertAI named as Outperformer among 15 other companies, including IQVIA, Tempus, and Datavant.
Loading...
Research containing ConcertAI
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned ConcertAI in 5 CB Insights research briefs, most recently on Aug 21, 2024.
Aug 21, 2024
The clinical trials tech market map
Expert Collections containing ConcertAI
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
ConcertAI is included in 8 Expert Collections, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
1,270 items
AI 100
100 items
The winners of the 4th annual CB Insights AI 100.
Conference Exhibitors
5,302 items
Digital Health 50
150 items
The winners of the second annual CB Insights Digital Health 150.
Digital Health
11,306 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Precision Medicine Tech Market Map
160 items
This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.
ConcertAI Patents
ConcertAI has filed 1 patent.
The 3 most popular patent topics include:
- artificial neural networks
- classification algorithms
- machine learning
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
10/29/2021 | Machine learning, Artificial neural networks, Classification algorithms, Machine learning algorithms, Statistical classification | Application |
Application Date | 10/29/2021 |
|---|---|
Grant Date | |
Title | |
Related Topics | Machine learning, Artificial neural networks, Classification algorithms, Machine learning algorithms, Statistical classification |
Status | Application |
Latest ConcertAI News
Apr 7, 2025
The funding round brings the company's total raise to $1.86 billion since it launched in 2018. Photo: poba/Getty Images Biotechnology and precision medicine company Caris Life Sciences announced it raised $168 million in growth capital funding. Caris Life Sciences has now raised $1.86 billion in capital since 2018. Braidwell LP led the round with participation from new investors Perceptive Advisors , Woodline and Ghisallo. Millennium Management and First Light Asset Management also participated in the round. WHAT IT DOES The company is involved in pathology and molecular profiling to diagnose and treat cancerous tissues. They use molecular science AI and machine learning algorithms to analyze cancer to help guide physicians in making treatment decisions. The company will use the money to grow its precision medicine platform and scale its reach. "This raise will help us bring our market-leading science and technologies to as many patients as possible and further our goal of revolutionizing precision medicine," David Halbert, chairman, founder and CEO of Caris, said in a statement. "We plan to unlock the full potential of precision medicine by comprehensively interrogating cancer at the molecular level and enabling the delivery of transformative applications of molecular science." MARKET SNAPSHOT In 2023, ConcertAI announced it expanded its partnership with Caris Life Sciences. The two companies created a database to generate insights to advance precision medicine, clinical trial management and therapeutic development. The partners developed a database that leverages both companies' clinical, molecular and multimodal data aimed at allowing academics and biopharma researchers to acquire insights for oncology-focused precision medicine, clinical trial management and therapeutic development. Other companies involved in precision medicine for cancer include ImpriMed , which in 2024 expanded its services to include human oncology with the aim of providing drug-response predictions for routine blood cancers, such as newly diagnosed multiple myeloma and acute myeloid leukemia. ImpriMed's human precision medicine services focus on complex blood cancers, using genomic analysis, machine learning and ex vivo drug sensitivity testing. In 2023, Pfizer announced a multiyear strategic alliance with Tempus to use AI and machine learning to inform drug discovery and development in oncology. Pfizer uses Tempus' library of de-identified data to increase therapeutic development in oncology. Additionally, it will use Tempus' AI-driven companion diagnostic tools and clinical trial-matching program to bolster therapeutic research and development. Tags:
ConcertAI Frequently Asked Questions (FAQ)
When was ConcertAI founded?
ConcertAI was founded in 2017.
Where is ConcertAI's headquarters?
ConcertAI's headquarters is located at 1120 Massachusetts Avenue, Cambridge.
What is ConcertAI's latest funding round?
ConcertAI's latest funding round is Series C.
How much did ConcertAI raise?
ConcertAI raised a total of $320M.
Who are the investors of ConcertAI?
Investors of ConcertAI include Sixth Street Partners, AllianceBernstein, Maverick Ventures Israel, Declaration Partners, SymphonyAI and 3 more.
Who are ConcertAI's competitors?
Competitors of ConcertAI include Aetion, Mendel AI, Zephyr AI, Holmusk, nference and 7 more.
Loading...
Compare ConcertAI to Competitors
Owkin is an AI biotechnology company that employs artificial intelligence to improve drug discovery and development in the biopharmaceutical sector. The company specializes in AI-based identification of new treatments, clinical trial optimization, and diagnostic tool creation, while ensuring patient privacy through federated learning techniques. Owkin serves the biopharma and academic research communities. It was founded in 2016 and is based in New York, New York.
Aetion provides real-world evidence solutions within the healthcare sector. The company offers software and services that analyze real-world data to provide insights on the safety, effectiveness, and value of medical treatments and technologies. Its clientele includes biopharma companies and government agencies to inform health care decisions and guide product development. It was founded in 2013 and is based in New York, New York.
Promptly Health offers real-world evidence solutions within the healthcare sector. The company provides services that include generating knowledge from clinical, socio-economic, and claims data, as well as collecting longitudinal patient-reported data and digital biomarkers. Promptly Health serves life sciences, healthcare providers, and healthcare payers. It was founded in 2017 and is based in Porto, Portugal.
Verantos specializes in real-world evidence within the life sciences sector. The company has a platform that combines various real-world data sources to produce research-grade evidence, using clinical narrative data and artificial intelligence technology. This evidence is used for market access, medical affairs, and regulatory initiatives across therapeutic areas. It was founded in 2015 and is based in Menlo Park, California.
nference is a healthcare technology company specializing in clinical artificial intelligence (AI) and evidence. The company offers a platform that uses healthcare data to manage clinical data, support research, and work with patient outcomes through artificial intelligence. nference primarily serves the healthcare sector, providing solutions for clinical researchers, data scientists, and healthcare systems. It was founded in 2013 and is based in Cambridge, Massachusetts.
Holmusk is a data analytics and health technology company that focuses on behavioral health within the healthcare sector. The company offers a real-world evidence platform that combines a behavioral health database with analytics and digital solutions to support research and care. Holmusk's services include HolCare EHR+, an electronic health records platform with measurement-based care, and NeuroBlu Research, a data analytics solution for building patient cohorts and exploring datasets. It was founded in 2015 and is based in New York, New York.
Loading...